摘要
近年来发现2型糖尿病与过氧化物酶增殖体活化受体(peroxisome proliferator-activated receptor,PPAR)存在着密切的联系,该受体也因此成为设计抗2型糖尿病药物的主要靶标。目前,有很多针对PPAR所设计的化合物处于临床研究阶段,现介绍这方面的进展,并阐述开发抗2型糖尿病药物所面临的困难及相应的策略。
It is found recently that close relationship existed between non-insulin dependent diabetes mellitus (NIDDM) and PPAR. Therefore, PPAR is now employed as a main target in developing anti-diabetics for treatment of NIDDM. Lately a lot of new chemical entities for treatment of NIDDM using PPAR as target at clinical trials have been developed. In this paper, progress in this aspect, and difficulties faced by developing anti-diabetics and their solutions are reviewed by the authors.
出处
《中国新药杂志》
CAS
CSCD
北大核心
2003年第12期980-983,共4页
Chinese Journal of New Drugs
基金
十五国家重大科技专项"创新药物与中药现代化"资助项目(No.2002AA2Z3146)
3项国家863资助项目(No.2002AA234041
2002AA234021
2002AA104270)
广东省2002年重大项目招标中标项目(No.2002-108)。
关键词
2型糖尿病
抗糖尿病药物
过氧化物酶增殖体活化受体(PPAR)
胰岛素增敏剂
non-insulin dependent diabetes mellitus (NIDDM)
anti-diabetics
peroxisome pro- liferator-activated receptor (PPAR)
insulin sensitizer
